Management

Bo Rode Hansen
Chief Executive Officer

Previously President and CEO of Genevant Sciences Inc. (MSc, Ph.D., MBA).
Previously, Global Head of Roche RNA Therapeutics, General Manager of Roche Innovation Center Copenhagen and Head of Drug Discovery & Alliance at Santaris (acquired by Roche).

Scandion Oncology shares and warrants
1.071.688 warrants

Nils Brünner
Chief Scientific Officer

MD, DMSc.
Professor University of Copenhagen.
Co-founder of Scandion Oncology A/S.

Scandion Oncology shares and warrants
1.085.370 shares (Partly owned via Timpco NB ApS)

Carit Andersen
Chief Financial Officer

Cand.Merc.
External lecturer, University of Southern Denmark.

Scandion Oncology shares and warrants
56.269 shares and 53.584 warrants (Partly owned via Decisionconsult Holding ApS)

Jan Stenvang,
Chief Technology Officer

MSc, PhD.
Associate Professor, University of Copenhagen.
Co-founder of Scandion Oncology A/S.

Scandion Oncology shares and warrants
1.391.064 shares

Peter Michael Vestlev
Chief Medical Officer

MD, CBA, MPP.
Chief Physician, Oncologist, Region Sjælland.
Previously, consultant for the Danish Medicines Agency.

Scandion Oncology shares and warrants
56.865 shares and 53.584 warrants

Nicklas Lindland Roest
Chief Regulatory Officer

MSc. Pharm.

Scandion Oncology shares and warrants
26.138 shares and 53.585 warrants (Partly owned via Lindland Roest Holding ApS)

Annie Rasmussen
Chief Clinical Officer

Registered Nurse, Special Diploma.

Scandion Oncology shares and warrants
3.500 shares and 53.585 warrants

Pipeline

Scandion Oncology has two promising compounds in the pipeline, including SCO-101, which has completed four Phase I trials, and SCO-201, which is in preclinical testing stages. We aim to conclude one Phase II trial within the next 2 years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.

Clinical Trials

Our lead compound – SCO-101 – has been shown to enhance the effect of certain standard chemotherapy when given in combination. We are planning two Phase II trials within metastatic colorectal cancer and metastatic breast cancer. We are simultaneously developing SCO-201, which will target other solid tumors.

Investors

Detailed analyses suggests the market for Scandion Oncology’s products to be more than EUR 4 billion annually. We believe our patents could be attractive for larger pharmaceutical companies to combine with their existing cancer treatments.

Co-funded by the Horizon 2020 programme of the European Union
Co-funded by the COSME programme of the European Union